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Abstract 
Rationale: Cell-free protein microarrays display naturally-folded proteins based on just-in-time in 
situ synthesis, and have made important contributions to basic and translational research. 
However, the risk of spot-to-spot cross-talk from protein diffusion during expression has limited 
the feature density of these arrays.  
Methods: In this work, we developed the Multiplexed Nucleic Acid Programmable Protein Array 
(M-NAPPA), which significantly increases the number of displayed proteins by multiplexing as 
many as five different gene plasmids within a printed spot.  
Results: Even when proteins of different sizes were displayed within the same feature, they were 
readily detected using protein-specific antibodies. Protein-protein interactions and serological 
antibody assays using human viral proteome microarrays demonstrated that comparable hits were 
detected by M-NAPPA and non-multiplexed NAPPA arrays. An ultra-high density proteome 
microarray displaying > 16k proteins on a single microscope slide was produced by combining 
M-NAPPA with a photolithography-based silicon nano-well platform. Finally, four new 
tuberculosis-related antigens in guinea pigs vaccinated with Bacillus Calmette-Guerin (BCG) were 
identified with M-NAPPA and validated with ELISA.  
Conclusion: All data demonstrate that multiplexing features on a protein microarray offer a 
cost-effective fabrication approach and have the potential to facilitate high throughput translational 
research. 
Key words: Cell-free protein microarray, Proteomics, Protein-protein interaction, Antibody, Biomarker. 
Introduction 
Protein microarrays display individual proteins 
at high density on a chemically-modified slide that 
can be tested simultaneously with high sensitivity, 
high specificity, and low reagent consumption. They 
have been widely applied in basic and translational 
research, such as protein interaction studies, immune 
profiling, vaccine development, biomarker discovery 
and clinical diagnostics, etc. [1-12]. For example, 
Zhang et al. used a human protein microarray to better 
understand how arsenic, which is used in 
chemotherapy, disrupts cancer signaling pathways 
and, further, to identify potential targets of novel 
therapeutic treatments. Of the 16,368 proteins that 
were screened, 360 arsenic binding proteins were 
identified, which may be novel targets for cancer 
treatment [7]. Anderson et al. used protein 
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microarrays to discover a 28-autoantibody biomarker 
signature of early stage breast cancer with a 
sensitivity and specificity of 80.8% and 61.6%, 
respectively [13]. By combining those autoantibodies 
with several protein biomarkers, Provista Diagnostics 
developed the first protein-based blood test for early 
breast cancer detection called Videssa® Breast [14]. 
Ayoglu et al. screened sera from multiple sclerosis 
(MS) patients using protein microarrays containing 
11,520 purified protein fragments and then validated 
those results using bead-based arrays [15]. The arrays 
indicated that Anoctamin 2 autoantibodies and the 
MS-associated HLA complex DRB1*15 allele were 
strongly associated. Additional experiments showed 
that Anoctamin 2 aggregates near and inside lesions 
within human MS brain tissue [15].  
 Protein microarrays can be classified into two 
different types, purified or cell-free, based on whether 
the proteins are produced in vivo or in vitro, 
respectively [16]. Purifying proteins is labor-intensive, 
requires method optimization and multiple 
manipulations, exhibits highly variable yields of 
different proteins, and may not result in 
naturally-folded or functional mammalian products 
due to expression in non-mammalian systems (e.g., E. 
coli, yeast). Cell-free protein microarrays overcome 
these challenges by depositing RNA or DNA on the 
slide surface and rapidly expressing them just before 
an experiment (~2 h) through the use of various 
cell-free expression systems (e.g., lysate from wheat 
germ, insect cells, rabbit reticulocyte and human 
cells). Compared to purified protein microarrays, 
cell-free protein microarrays are more likely to 
produce naturally-folded mammalian proteins due to 
the decreased sample manipulation and use of 
enhanced cell extracts with native chaperone proteins. 
Moreover, the use of nucleic acids vastly simplifies 
the production of custom arrays since any protein can 
be produced as long as the gene-of-interest is 
synthesized; for example, arrays can be produced that 
represent a specific proteome or signaling pathway 
[17-20].  
A primary disadvantage of planar-based 
cell-free protein microarrays is the diffusion of mRNA 
or expressed proteins during in vitro transcription and 
translation (IVTT), which can then be captured by 
neighboring features (i.e., cross-talk). Thus, the closer 
the features are to each other, the higher the cross-talk 
[21-24]. Planar-based cell-free protein microarrays 
include the protein in situ array (PISA) [22], DNA 
array to protein array (DAPA) [25], nucleic acid 
programmable protein array (NAPPA)[18, 26-28], and 
in situ puromycin-capture array [29]. DAPA, NAPPA 
and puromycin-capture arrays employ a probe (e.g., 
Ni-NTA or anti-tag antibody) on a microarray surface 
that captures the expressed recombinant proteins in 
situ during IVTT.  
Of the cell-free approaches, NAPPA has 
achieved the highest densities with ~ 2,300 plasmids 
per slide where the distance between neighboring 
spots is 625 µm) and the cross-talk is less than 2%. 
However, cross-talk is increased when the feature 
spacing is reduced to 375 µm [21]. With ~ 2,300 
plasmids per slide, five NAPPA slides are needed to 
screen a proteome-scale array with over 10,000 genes 
[18, 30]. Therefore, an increase in spot density would 
reduce the amount of labor, time, reagents, and cost 
needed for large-scale proteome analyses like target 
discovery and validation experiments. 
 To address this issue, Angenendt et al. printed 
cDNA and expressed the proteins in nanowells using 
piezoelectric dispensers [31]. Takulapalli et al. 
demonstrated the fabrication of high-density cell-free 
protein arrays by combining photolithographically- 
etched silicon nanowells (n=8,000/slide), NAPPA, 
and a piezo-inkjet printer [21].  
 Here we utilized a different strategy to produce 
high density arrays that does not require any 
specialized equipment or substrates. We developed 
the Multiplexed Nucleic Acid Programmable Protein 
Array (M-NAPPA) method by combining as many as 
five different DNA plasmids within one spot, which 
increases the number of displayed proteins per 
microarray by five-fold.   
 We first demonstrate that multiplexed proteins 
are displayed on M-NAPPA using protein-specific 
antibodies. Second, we compare the ability of 
M-NAPPA with non-multiplexed NAPPA to detect 
different protein-protein interactions and the 
serological antibody reactivity against 646 viral 
proteins. Next, we show the feasibility of M-NAPPA 
in performing high throughput screening for 
immune-dominant tuberculosis (TB) antigens through 
the use of an ultra-high density M-NAPPA TB 
proteome array containing four subarrays with 4,045 
TB open reading frames (ORFs) on one slide. Using 
M-NAPPA TB protein microarrays, four new 
immune-dominant antigens in the sera of 
BCG-vaccinated guinea pigs were identified, which 
were then validated using ELISA. Finally, we propose 
a high throughput target discovery and verification 
pipeline based on the M-NAPPA approach.  
Materials and Methods 
Sera samples 
All sera samples were collected with written 
informed consent with the approval of Institutional 
Review Boards (IRB) at University of Florida 
(Gainsville, FL), Arizona State University (Tempe, 
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AZ) and Albert Einstein College of Medicine (Bronx, 
NY). Detailed sample information was provided in 
our previous work [17, 20]. The sera from guinea pig 
TB models vaccinated with BCG were kindly 
provided by Dr. David N. McMurray from Texas 
A&M College of Medicine [32]. All experiments using 
clinical sera samples were executed according to the 
Declaration of Helsinki.  
Generation of mathematical model 
A mathematical model was built based on a 
two-step analysis process. The first round of screening 
would use multiplexed plasmids with the primary 
objective of identifying potential protein “hits.” The 
second round would be non-multiplexed, in which 
each multiplexed “hit” from the first round would be 
printed separately, with the primary goals of 
validating and identifying specific individual hits.  
 The total number of printed spots (N) needed 
for the combined two-round screening of 10k proteins 
was determined by the number of plasmids printed 
per spot and the anticipated hit rates (i.e., percentage 
of displayed proteins that will be identified as 
significant in the study). The probability p of an 
individual protein being a true hit can be estimated 
from previous studies of a similar nature (e.g., 
antibody biomarkers). The following equation 
assumes that p follows a Bernoulli distribution and 
that its corresponding plasmid is randomly 
multiplexed where the number of different plasmids 
per spot is k:  
𝑁𝑁 = 𝑛𝑛 × �1
𝑘𝑘
+ ��𝑘𝑘
𝑖𝑖
� 𝑝𝑝𝑖𝑖(1 − 𝑝𝑝)𝑘𝑘−𝑖𝑖𝑘𝑘
𝑖𝑖=1
� 
The number of spots needed in the first round is 
𝑛𝑛
𝑘𝑘
, The probability that a multiplexed spot would be a 
hit (i.e., containing at least one immune-dominant 
antigen) is ∑ �𝑘𝑘𝑖𝑖�𝑝𝑝
𝑖𝑖(1 − 𝑝𝑝)𝑘𝑘−𝑖𝑖𝑘𝑘𝑖𝑖=1  . The number of spots 
needed in the second round is 𝑛𝑛
𝑘𝑘
× ∑ �𝑘𝑘𝑖𝑖�𝑝𝑝𝑖𝑖(1 −𝑘𝑘𝑖𝑖=1
𝑝𝑝)𝑘𝑘−𝑖𝑖 × 𝑘𝑘 . The optimal level of multiplexing of k 
different plasmids per spot results in the smallest N.  
M-NAPPA preparation 
All human and viral ORF plasmids were 
obtained from DNASU (https://dnasu.org/), and 
transferred into a T7-based mammalian expression 
vector, pANT7-cGST, as previously described [18, 30, 
33]. Purified DNA plasmids were prepared by our 
automated DNA factory robot as previously 
described [18, 30, 33], and were normalized to 1,200 
ng/μL, such that multiplexed plasmids contributed 
equally to the final concentration. In other words, a 
plasmid in a five-multiplexed spot would represent 
240 ng/μL. Five (5) different plasmids containing a 
different gene-of-interest were mixed with a master 
printing mixture containing BSA (Sigma), BS3 
cross-linker (Thermo Fisher Scientific, IL) and 
polyclonal α-GST antibody (Thermo Fisher Scientific, 
IL)[26], and subsequently incubated at 4 oC for 2 h. 
M-NAPPA and NAPPA were printed by the NAPPA 
Protein Array Core (http://nappaproteinarray.org/) 
according to published protocols [18, 30, 33]. The 
quality of printed plasmid DNA on M-NAPPA and 
NAPPA was determined using PicoGreen DNA 
staining [26].  
Detection of protein expression on M-NAPPA  
Each M-NAPPA microarray was blocked with 
Superblock solution (Pierce, Rockford, IL) for 1 h at 23 
°C, briefly washed with water, centrifuged at 1000 
rpm for 3 min to dry, and covered with a 
hybridization chamber (Grace BioLabs, OR). The 
array was then incubated with 160 μL of human in 
vitro transcription & translation (IVTT) solution 
containing human HeLa cell lysate, accessory 
proteins, reaction mixture, and nuclease-free water 
(Thermo Fisher Scientific, IL) for 1.5 h at 30 °C and 0.5 
h at 15 °C to express the GST-tagged 
proteins-of-interest. The GST-tagged proteins were 
displayed on the slide surface via the polyclonal 
α-GST antibody that was included in the printing 
mixture. Then, the resulting protein microarray was 
incubated with 5% (w/v) milk in 1xPBS with 0.2% 
(v/v) Tween-20 (PBST) for 1 h at 23 °C, followed by 
three brief washes with PBST. The protein specific 
antibodies were diluted with 5% milk-PBST at 1:50 or 
1:100, respectively, and incubated with the protein 
microarray for 16 h at 4 °C followed by a 1 h 
incubation at 23 °C with an Alexa Fluor 555 labeled 
secondary antibody (Jackson ImmunoResearch 
Laboratories, PA). After washing three times with 
PBST, the M-NAPPA slides were briefly rinsed with 
water and dried by centrifugation (2,000 rpm, 2 min). 
The arrays were scanned by a Tecan scanner 
(Männedorf, Switzerland). 
Detection of protein-protein interactions on 
M-NAPPA  
After proteins were expressed on M-NAPPA, the 
resulting protein arrays were blocked with blocking 
buffer (1×PBS, 1%Tween 20 and 1% BSA, pH 7.4) for 1 
h at 4 oC. In parallel, the query proteins (e.g., Rb1, Jun, 
Fos, LidA) fused to a HaloTag were produced by 
incubating 90 ng of DNA in 180 µL human cell-free 
expression system (Thermo Fisher Scientific, IL) for 2 
h at 30 oC. To screen protein-protein interactions, the 
protein array was incubated with unpurified 
Rb1-Halo protein in human HeLa lysate for 16 h at 4 
oC, and then washed with cold washing buffer (PBS, 5 
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mM MgCl2, 0.5% Tween20, 1% BSA and 0.5% DTT, 
pH 7.4 at 4 oC) three times to remove unbound 
molecules. The arrays were consecutively incubated 
with a chicken anti-Halo tag antibody (GeneTel, WI) 
and Alexa Fluor 555 goat anti-chicken secondary 
antibody (Jackson ImmunoResearch Laboratories, 
PA) for 2 h at 4 oC. Arrays were washed and dried 
with brief centrifugation at 1,000 rpm for 1 min, and 
scanned as described above. The protein binding 
signal was quantified using Array-Pro Analyzer 
(Media Cybernetics) software as previously reported 
[20, 33].  
Data visualization 
For a given experiment, a tab-separated file with 
the interaction information was generated and loaded 
into the Cytoscape software [34] with an attribute file 
that contained signal intensities of features on 
M-NAPPA and NAPPA. In Figures 4 and 5, proteins 
within a multiplexed M-NAPPA feature and its five 
corresponding non-multiplexed proteins on NAPPA 
were displayed as connecting large and small nodes, 
respectively, with color gradients depicting signal 
intensities. 
Detection of serological antibodies on 
M-NAPPA  
After proteins were expressed on M-NAPPA, the 
arrays were blocked with 5% milk-PBST for 1 h and 
then incubated with sera at 1:300 dilution in 5% 
milk-PBST for 16 h at 4 °C. After washing three times 
with PBST, the resulting arrays were incubated with 
Alex Fluor 555 labeled anti-human IgG antibody 
(Jackson ImmunoResearch Laboratories, PA) 1 h at 23 
°C. The slides were washed with PBST, briefly rinsed 
with water, and dried by centrifugation (2,000 rpm, 2 
min). The fluorescent scanning was performed using a 
Tecan scanner (Männedorf, Switzerland). The 
antibody binding event was quantified by 
fluorescence signal intensity using Array-Pro 
Analyzer (Media Cybernetics) software as previously 
reported [20, 33].  
Results 
Conception of M-NAPPA  
Protein microarrays have been used in functional 
protein and antibody biomarker studies to screen for 
target(s)-of-interest, which are generally rare in the 
tested protein population (Figure 1B). For example, 
the median hit rates (± standard deviation, SD) of 
studies employing protein microarrays in the past five 
years for screening protein function and autoantibody 
biomarkers (Table S1) were 0.49% ± 1.23% and 1.02% 
± 4.46%, respectively (Figure 1B). Since false positives 
are not uncommon during initial screens, all initial 
candidates require an independent verification step 
performed using different samples [5, 7, 8, 19, 35-37]. 
Considering that a two-step approach for target 
discovery and verification often uses hundreds to 
thousands of samples, the cost of such studies using 
full-scale arrays can be inhibitory.  
To decrease the cost of high throughput 
screening experiments, we hypothesized that the 
plasmid cDNA encoding for different proteins could 
be multiplexed (by combining M different plasmids) 
within each feature to create a high-density array, 
M-NAPPA (Figure 1A). This multiplexed array could 
be implemented during the initial functional screen, 
testing entire proteomes (P proteins) using only a 
fraction of the features (P/M). Multiplexed hits 
identified during the screening step could then be 
de-convoluted in the subsequent verification step 
using the standard, non-multiplexed NAPPA array 
where each feature displays only one protein (i.e., 
M=1). The objectives of the second step would be to 
identify which proteins were responsible for the 
positive multiplexed signal and to verify whether the 
hits were real. This approach exploits the high 
flexibility of cell-free microarrays, in which arrays can 
be customized by simply re-arraying individual 
plasmids encoding for the multiplexed 
features-of-interest. 
The schematic illustration of how M-NAPPA 
arrays are processed is shown in Figure 1A. Using a 
standard pin-based arrayer, each spot on M-NAPPA 
contains plasmids encoding for different 
proteins-of-interest with the same fusion tag. The 
genes are then transcribed and translated into 
recombinant proteins in two hours using a cell-free 
expression system, and captured to the slide surface in 
situ via a fusion tag antibody.  
The optimal number of proteins to multiplex 
depends upon several factors, including hit 
frequency, cost, array space, and number of proteins. 
As the frequency of hits in the screen increases, more 
proteins will need to be tested as individual features 
during the verification step. Taken to the extreme, if 
one protein per multiplexed feature were a hit (hit 
rate = 1/M), all multiplexed features would require 
deconvolution, making the multiplexing approach 
impractical. However, such a high hit rate is not 
reflected by data collected by numerous studies; for 
example, the hit rate was < 5% in most of our previous 
NAPPA-based screening studies with 10k human 
genes (Figure 1B). We generated a mathematical 
model (Materials and Methods) to find the optimal M 
that would take into consideration array space and 
the cost of screening and verifying hits using our 10k 
protein human collection at different hit rates. In 
Figure 1C, the x-axis represents the number of genes 
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per spot (M) while the y-axis represents the number of 
spots or proteins that are needed for the two-step 
screening process. Notably, when the hit rate is < 5% 
for 10k proteins, a relatively small number of spots 
would be needed for the entire study (screening + 
verification) with 5 proteins multiplexed per feature 
in the initial screen, thus representing a good 
compromise between the number of initial features 
screened and the subsequent number of features that 
would be needed for deconvolution and verification.  
Comparison of protein display by NAPPA and 
M-NAPPA   
To assess the difference in 
transcriptional/translational efficiency as well as 
display competition between large and small proteins 
within one feature, we multiplexed proteins of 
varying molecular weights (MW; 20 – 124 kDa) 
covering 80% of the size range in our human protein 
collection (Figure S2) on M-NAPPA. As indicated in 
Figure 1, we prepared NAPPA and M-NAPPA slides 
in parallel where NAPPA had only one plasmid per 
spot and M-NAPPA multiplexed five plasmids per 
spot. After IVTT, the protein arrays were probed with 
eight antibodies that bound targets ranging in size 
from 20 to 106 kDa (Methods and Figure S1). These 
antibodies were specific to IA-2 (106 kDa), GAD2 (65 
kDa), Clusterin (52 kDa), p53 (44 kDa), Fos (40 kDa), 
PP2A (36 kDa), SFN (28 kDa) and BCL2L2 (20 kDa). 
We compared the protein display between the 
two array types using groups of five proteins with 
either similar (Figure 2A and Figure 2B) or varied 
molecular weights (Figure 2A and Figure 2C), and 
then calculated the signal ratio of M-NAPPA to 
NAPPA. In both cases, all of the antibodies readily 
detected their corresponding antigens. For the spots 
with similarly-sized proteins (36 kDa to 85 kDa), the 
signal ratio of M-NAPPA to NAPPA was 0.78±0.44. 
For the spots containing five proteins covering a wide 
range of molecular weight, from 29 kDa to 106 kDa 
(Figure 2C), the binding signal ratio of M-NAPPA to 
NAPPA was 1.03±0.75 (Figure S3). Thus, 
multiplexing proteins of similar size did not confer 
any advantage over random multiplexing.  
 
 
Figure 1. Multiplexed proteins per feature is made possible by low hit rates in HT screening studies. (A) Schematic illustration of unbiased target 
discovery using M-NAPPA protein microarrays where each spot contains five gene plasmids encoding for different proteins. The hits identified from high-density 
M-NAPPA protein microarrays could be deconvoluted by non-multiplexed NAPPA arrays. (B) Percentage of hits identified in high throughput protein function and 
autoantibody biomarker studies in 37 publications within the last five years. (C) Plot of the total number of features needed to evaluate hits in a primary screen 
followed by verification study at different multiplicities and hit rates. The red arrow points to the optimal number of genes printed within each spot for 10k proteins 
with an estimated hit rate of 5%.  
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Figure 2. Protein display on M-NAPPA arrays. (A) Distribution of molecular weights for the proteins used in protein display examination. Five proteins with 
either (B) similar molecular weights (36 kDa to 85 kDa) or (C) a wider range of molecular weights (29 kDa to 106 kDa) were displayed as mixed (M) or as individual 
(N) proteins. Protein levels were assessed by probing the array with antibodies that target each protein (e.g., IA2, GAD2, p53, Fos, SFN, and BCL2L2). The 
fluorescence signal intensity (MFI) for each protein was compared between the M and N groups by calculating the M/N ratio. Abbreviations ms and rt are for mouse 
and rabbit, respectively. 
 
To further demonstrate that there were no biases 
in the expression of different proteins produced from 
mixed plasmids, five-plasmid mixtures containing 
various combinations of seven different genes (Abl1, 
IA-2, GAD2, Jun, RhoU, BCL2L2 and MT3033) were 
co-expressed in IVTT solution and analyzed via 
western blot. Despite a wide range of protein sizes, all 
proteins were expressed at similar amounts in their 
relevant combinations (Figure S4). 
These data indicate that, although each plasmid 
in M-NAPPA is present at one-fifth the amount 
present in standard NAPPA, there was no significant 
difference of protein display levels between the arrays 
(p-value = 0.36, paired sample t-test). In addition, 
background signals that resulted from non-specific 
antibody binding were comparable between the 
platforms, demonstrating that multiplexing does not 
result in an accumulation of background signal that 
could contribute to the identification of false positives 
(Figure S5). Therefore, we randomly mixed different 
gene plasmids in the following M-NAPPA studies.  
To demonstrate that the signal intensity for 
M-NAPPA was reproducible, we also tested the 
spot-to-spot, zone-to-zone and slide-to-slide 
variations by printing 80 gene plasmids on different 
locations across the M-NAPPA and NAPPA slides. 
Protein display was then examined with anti-GST 
antibody staining (Materials and Methods). The 
coefficient of variations (CVs) for spot-to-spot, 
zone-to-zone and slide-to-slide were 3.64±3.27%, 
7.57±3.41% and 7.27±4.00% for M-NAPPA, 
respectively, and 7.63±10.58%, 12.13±7.56%% and 
13.25±9.42%% for NAPPA, respectively (Table S4).  
Performing functional assays using M-NAPPA 
arrays 
Fabrication of viral M-NAPPA protein microarrays  
We purified 646 viral ORF plasmids from ~23 
viruses, normalized their concentrations to 1,200 
ng/µL, and printed viral NAPPA and M-NAPPA 
arrays in duplicate [20]. Analyses of the deposited 
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DNA and displayed protein levels indicate that most 
viral DNA plasmids were successfully printed, 
expressed, and captured onto the microarrays in a 
reproducible manner (Figure 3A). For example, 
plasmid DNA deposition across technical replicates of 
NAPPA and M-NAPPA had correlations (R) of 0.95 
and 0.96, respectively. The protein display correlation 
(R) across technical replicates of NAPPA and 
M-NAPPA were 0.90 and 0.93, respectively (Figure 
3B, Figure S6). “Non-spots” containing printing 
buffer alone without plasmid DNA was used as a 
negative control. 94% and 93% of the spots on NAPPA 
and M-NAPPA viral arrays, respectively, produced 
signal that was at least two SDs above the average 
signal intensity of these “non-spots” (Figure S7). 
Together with Figure 2, the results indicate that the 
majority of viral proteins can be displayed on 
M-NAPPA arrays.  
In addition, we compared the S/B (signal to 
background) ratios between direct fluorescence and 
tyramide signal amplification (TSA) using a 
fluorophore-linked or HRP-conjugated anti-p53 
antibody, respectively. Using the signal from 
“non-spots” as background, we found that the S/B 
ratio of fluorescence detection using an antibody with 
a directly-conjugated fluorophore, the Dylight649 
rabbit anti-mouse IgG, was higher (S/B ratio = 
431±38) than the TSA method with the HRP-labeled 
goat anti-mouse IgG (S/B ratio = 323±18). Thus, 
directly-conjugated fluorescent secondary antibodies 
were used for the following assays (Figure S8).  
Performing protein-protein interaction assays using 
M-NAPPA  
To determine whether NAPPA and M-NAPPA 
detect similar protein-protein interactions, both arrays 
were programmed to display proteins that are known 
to interact with the tumor suppressor protein Rb1. 
The arrays were then probed with a Rb1 query protein 
fused to HaloTag, and interactions were detected 
using an anti-HaloTag antibody. The Rb1-HaloTag 
query protein bound to several targets (red arrow) on 
NAPPA and M-NAPPA arrays; the query also bound 
to diffused targets outside of each spot, which appear 
as a “ring” around each feature (Figure 4A). In Figure 
4B, we used a flower pattern diagram to depict the 
multiplexed proteins on M-NAPPA (large central 
circle) and the deconvoluted individual proteins on 
NAPPA (five small connecting circles) (Materials and 
Methods). The blue gradient within the spot indicates 
target binding to the Rb1 query protein, whereas 
reactivity to the “ring” [20, 33] is indicated by a red 
circle around the spot. Using custom defined criteria, 
where the target-to-“non-spot” signal ratio is > 2 and 
the ring score is > 3, we found that 5 and 6 hits were 
identified on NAPPA and M-NAPPA, respectively, 
out of the 30 possible candidate target proteins (Table 
S2, Table S3). Five of the 6 hits on M-NAPPA were 
E1A, HPV11-E7, HPV16-E7, HPV18-E7 and 
HPV33-E7, which agrees with previous studies 
[38-40]. The sixth hit on M-NAPPA was not detected 
with NAPPA, thus suggesting that the hit may be a 
false positive.  
 
 
Figure 3. Fabrication of viral M-NAPPA microarrays. (A) Representative images of printed plasmid DNA (via Picogreen) and displayed protein (via anti-GST 
antibody to the fusion tag) on M-NAPPA and NAPPA; (B) Technical reproducibility of DNA deposition and protein display for M-NAPPA and NAPPA arrays.  
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Figure 4. Detection of protein-protein interactions on M-NAPPA. (A) Representative images of Rb1-HaloTag binding to its known protein targets on 
M-NAPPA and NAPPA, which were detected using a chicken anti-HaloTag antibody and Alexa555 goat anti-chicken antibody. Rb1’s protein partners are indicated 
with a red arrow. False-colored images across a rainbow scale corresponds to the relative level of Rb1 binding signal, where low and high Rb1 binding levels are 
represented by blue and red, respectively; (B) Multiplexed features on M-NAPPA (large circle) and the deconvoluted features on NAPPA (smaller connecting circles) 
that bound to Rb1-HaloTag. The blue scale bar corresponds to the relative level of Rb1 binding signal within the spot while the white-to-red color scale corresponds 
to the level of Rb1 binding signal to diffused target protein outside of the spot (i.e., “ring”).  
 
To further examine the utility of M-NAPPA to 
test protein-protein interactions, additional 
interactions were analyzed with 35 displayed proteins 
on NAPPA and M-NAPPA using HaloTagged-Jun, 
-Fos, and -LidA queries. Jun, Fos and LidA bound to 
their expected interaction partners (i.e., Fos, Jun and 
three Rab family proteins, respectively) on both 
M-NAPPA and NAPPA arrays (Figure S9). Regarding 
the protein interactions that were identified, the 
spot-to-spot and zone-to-to zone CVs were 
5.65±2.69% and 5.75±3.86% for NAPPA, respectively, 
and 2.55±2.56% and 3.11±3.46% for M-NAPPA, 
respectively (Table S5).  
These results indicate that M-NAPPA can be 
used for preliminary high throughput (HT) screening 
of novel protein-protein interactions. The screen can 
then be followed by a verification step using 
deconvoluted spots via NAPPA to identify the 
specific proteins that are involved. 
Identification of serological antibodies using 
M-NAPPA 
To test whether M-NAPPA can be used to detect 
proteomic serological response, we screened ten 
serum samples from patients with type 1 diabetes that 
had been previously characterized using NAPPA 
arrays [20]. A dozen hits were observed with 
M-NAPPA and NAPPA (Figure 5). Forty-nine of the 
53 antigens (92.5%) identified by NAPPA were also 
detected by M-NAPPA. Four antigens, however, were 
detected with only one platform (i.e., two with 
NAPPA, two with M-NAPPA). These uncommon 
discrepancies may be due to variations in surface 
chemistry, plasmid concentration, printing or array 
processing.  
High throughput identification of 
immune-dominant antigens using M-NAPPA 
tuberculosis proteome microarrays 
Since the multiplex concept to increase feature 
density was successful in detecting protein-protein 
interactions and serological antibody responses on 
planar microarrays, we wanted to determine whether 
M-NAPPA could also be applied to a nano-well 
microarray platform. We previously increased feature 
number by printing plasmids into 
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photolithography-etched silicon nano-wells to create 
a high-density NAPPA (HD-NAPPA) platform [41]. 
HD-NAPPA can have as many as 10k features per 
slide, and has successfully detected antiviral 
antibodies in autoimmune diseases with 761 different 
proteins displayed on the array in quadruplicate. 
These tiny wells hold only 1200 pL and use only 0.12 
ng of plasmid DNA. We applied the multiplex 
concept to HD-NAPPA using a mixture of plasmids 
encoding for IA-2, GAD2 and p53 proteins. We then 
detected their expression and display using specific 
antibodies; all of these proteins were readily 
detectable when printed as a three-plexed mixture 
(Figure S10). We then multiplexed 4,045 tuberculosis 
(TB) ORFs [32] onto HD-NAPPA microarrays as four 
separate subarrays using three gene plasmids per well 
(M=3), resulting in an M-HD-NAPPA microarray 
displaying > 16k proteins on a single slide. This lower 
multiplicity was based on the mathematical model 
(Figure 1C) that took into account that the high 
number of conserved proteins in endemic, 
non-pathogenic mycobacterial species results in a 
higher hit rate (~10% [37]).  
Over 95% of the spots generated a signal that 
was at least 10 SDs above the background, which 
indicates that the vast majority of proteins were 
well-expressed and displayed (Figure 6A), with a 
correlation of R = 0.90 across technical replicates 
(Figure 6A-C). Antibody reactivity from TB patient 
sera was observed with M-HD-NAPPA (Figure 6D). 
The technical reproducibility of these 
immune-dominant antigens across different 
M-NAPPA arrays using the same sera was very high, 
with a correlation of R = 0.98 (Figure 6D-F). All 
immune-dominant antigens identified with 
M-HD-NAPPA screening were then deconvoluted in 
the verification step using single protein NAPPA 
(Figure 6G) and validated with RAPID-ELISA as 
previously described [19] (Figure 6H).  
 
 
Figure 5. Detection of serological antibodies on viral M-NAPPA arrays. (A) Representative images of viral antibody detection on M-NAPPA and NAPPA; 
(B) Comparison of anti-viral antibodies binding to their displayed protein antigens on M-NAPPA (large circle of five multiplexed genes) and NAPPA (small circle of 
deconvoluted genes). The blue scale bar corresponds to the relative level of antibody binding signal. 
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Figure 6. M-NAPPA TB proteome microarray fabrication, protein display, and role in detecting immune-dominant antigens. (A) Representative 
image of protein display on M-NAPPA TB proteome microarrays; (B) Distribution of protein display across four M-NAPPA TB proteome microarrays using an 
antibody specific to the capturing fusion tag; (C) Correlation of protein display across different TB proteome microarrays; (D) Representative image of serological 
antibody detection on an M-NAPPA TB proteome microarray; (E) Distribution of serum antibody binding signals on a M-NAPPA TB proteome microarray; (F) 
Correlation of serological antibody detection using M-NAPPA TB proteome microarrays; (G) Deconvoluted and verification of TB antibody candidates from 
M-NAPPA using NAPPA protein microarrays; (H) Validation of a reactive serological antibody on M-NAPPA and NAPPA using ELISA. (A, D, G) False-colored images 
across a rainbow scale where low and high binding are represented by blue and red, respectively. 
 
We screened the sera from guinea pigs 
immunized with Bacillus Calmette-Guerin (BCG), a 
TB vaccine, using M-HD-NAPPA TB proteome 
microarrays. The aim of this experiment was to 
identify potential protective antibodies induced with 
BCG. The representative fluorescence images are 
shown in Figure 7A. Compared to the control mock 
sera pool using PBS buffer (n=5), four features on 
M-NAPPA arrays showed increased signals with the 
BCG samples (n=4) (Figure 7B). To deconvolute and 
validate those targets, we repeated the serological 
assay for those candidate proteins, along with two 
non-responsive control proteins (Rv2077A and 
Rv2682c), using RAPID-ELISA and the individual 
sera from the guinea pigs. The antibody levels of four 
antigens (Rv3405c, Rv1078, Rv2853 and Rv0928) in 
BCG-vaccinated guinea pigs were significantly higher 
than that of the PBS control with a p-value <0.01 
(Figure 7C, Figure S11). According to the Tuberculist 
database (http://tuberculist.epfl.ch/), these proteins 
are involved in regulation, cell wall and cell processes, 
and are considered to be in the proline-glutamic acid 
/ proline-protein-glutamic acid (PE/PPE) protein 
families (Figure 7D).  
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Figure 7. Serological antibody response induced by the BCG vaccine in guinea pigs. (A) Discovery of antibody hits using M-NAPPA TB proteome 
microarrays using the sera pool from guinea pigs immunized with the BCG vaccine (n=4) or PBS (negative control, n=5); (B) The four top hits with increased antibody 
signal in guinea pigs vaccinated with BCG; (C) Deconvolution and verification of antigens using RAPID-ELISA and individual guinea pig sera. The p-value was calculated 
using an un-paired Man Whitney t-test. * p-value ≤0.01, ** p-value ≤0.001, *** p-value ≤0.001; (D) Annotation of identified TB antigens associated with the BCG 
vaccine. 
 
A primary advantage of cell-free protein 
microarrays is that the arrays have a long shelf life. 
We compared the protein expression of M-NAPPA TB 
arrays immediately after printing and then again after 
6 months of storage at room temperature in a nitrogen 
atmosphere. A GST-tagged protein, detected with an 
anti-GST antibody, was considered to be displayed if 
it had a signal that was two SDs above the signal of 
the “non-spots.” Over 99% of the proteins were 
displayed on new M-NAPPA arrays; this number, as 
well as the anti-GST signal intensity, did not change 
even after 6 months of storage (Figure S12).  
Discussion 
NAPPA has been widely applied in 
protein-protein interactions, post-translational 
modifications (PTMs), antibody epitope mapping and 
discovery of (auto) antibody biomarkers for a variety 
of human diseases, including markers that are 
currently being used in the clinic for the detection of 
breast cancer [13, 14, 18, 20, 32, 36, 42-44]. Due to 
mRNA and protein diffusion during IVTT, the 
number of features per planar microscope slide has 
been limited to ~2,300 to minimize cross-talk to 
neighboring spots. The feature density limit has thus 
required that multiple slides be used to study large 
proteomes. 
Here, we developed a new strategy, M-NAPPA, 
that significantly increases the number proteins that 
can be tested per slide multiple-fold. By combining 
five different plasmids within one feature, >10k 
proteins can be printed on one microscope slide for 
HT, low cost analyses when compared to studies 
using one-plasmid-per-feature arrays. The 
multiplexed hits that are identified with M-NAPPA 
can then be deconvoluted during the subsequent 
verification step (Figure 8). 
First, we constructed a mathematical model to 
determine the optimal level of multiplexing, which 
considers the number of proteins, cost, array size, and 
hit rate to predict the number of arrays that would be 
needed for a two-step screening and verification 
study. A survey of HT unbiased target screening 
studies that used protein microarrays, both in the 
literature and our own results using NAPPA, revealed 
that hits are rare (typically <5%) (Figure 1B). For 10k 
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proteins and a hit rate of 5%, the mathematical model 
indicated that multiplexing 5 proteins per spot 
(Figure 1C) would provide a good balance of 
maximizing the number of features, minimizing the 
number of arrays, and yielding the minimum overall 
workload when compared to using non-multiplexed 
arrays for both the screening and verification steps.  
Second, we demonstrated that there was nothing 
inherent to printing plasmids as a five-plasmid 
mixture that prevented their expressed proteins from 
routine detection regardless of protein size. However, 
display levels of large proteins (> 65 kD) were 
decreased by 60±0.1% for GAD2 and 63±11% for IA-2 
(Figure 2C). This may be because the plasmids were 
mixed equally together based on their masses, a 
requirement imposed by the printing chemistry; this 
would result in a lower molarity of large plasmids 
(i.e., large proteins) relative to small plasmids in the 
printing mixture. Another possible reason is that 
larger proteins are produced more slowly than 
smaller proteins due to their longer mRNA sequences.  
Third, we showed that M-NAPPA can be used in 
protein-protein interaction and serological screening 
studies. The results from M-NAPPA agreed strongly 
with those observed with non-multiplexed NAPPA 
(Figure 3-5, Table S2 and S3, Figure S9). These data 
indicate that M-NAPPA presents a labor- and 
cost-effective strategy to initially screen for hits.  
Fourth, we further increased the feature density 
by applying this method to our previously-published 
nano-well platform [21]. With M-HD-NAPPA, the 
entire TB proteome containing 4,045 genes was 
successfully printed on a nano-well array in 
quadruplicate [20] (Figure 6). This generates the 
highest density nano-well protein microarray to date 
and increases the previously demonstrated content by 
more than five-fold [20]. Our data indicate that the 
multiplexing strategy has great potential value for use 
with different microarray platforms (Figure 6 and 
Figure 7) [45].  
Finally, we evaluated the reproducibility of 
M-NAPPA arrays for protein array preparation and 
protein-protein interactions. We found M-NAPPA can 
be reproducibly fabricated with spot-to-spot, 
zone-to-zone and slide-to-slide CVs that are similar to 
those obtained with NAPPA (Table S4). The 
spot-to-spot and zone-to-to zone CVs for 
protein-protein interactions were also similar between 
the two array platforms (Table S5). While the 
correlations within and between different M-NAPPA 
slides were good (i.e., R = 0.93 for both) (Figure 3 and 
Figure S6), with some size adaptation, the 
reproducibility could eventually be further improved 
with the use of automation equipment like the HS 
4800 Pro Hybridization Station (Tecan Trading AG; 
Männedorf, Switzerland). 
 
 
Figure 8. M-NAPPA can be used for target discovery in HT screening. The identified hits on M-NAPPA can be verified by a small array containing those 
deconvoluted candidates, and further validated using an independent in vivo or in vitro assay. 
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In some ways, M-NAPPA resembles “natural 
protein” microarrays that print unpurified or partially 
fractionated proteins from lysates of human cells, 
tissues or body fluids, but in a much more controlled 
manner. Each feature of a natural protein microarray 
typically represents a mixture of unknown proteins. 
Thus, responsive hits on natural protein arrays 
require a challenging and time-consuming process to 
determine the identity of the protein responsible for 
the response. This may require further purification, 
identification by mass spectrometry and additional 
response testing of recombinant proteins [46, 47]. In 
the case of M-NAPPA, the identities of the proteins in 
each mix are known in advance and the plasmids 
encoding for each protein are available for secondary 
testing.  
M-NAPPA would be useful in unbiased HT 
screening studies, such as protein-protein 
interactions, protein-DNA interactions, discovery of 
drug binding target as well as (auto)antibody 
biomarkers for a variety of human diseases. However, 
it should be noted that there are situations in which 
using a non-multiplexed array format would be more 
appropriate. For example, NAPPA should be used 
when investigating protein functions or when the 
number of proteins to be screened is low. Additional 
attributes of M-NAPPA should be considered as well. 
Large, multiplexed proteins (> 65 kDa) on M-NAPPA 
are displayed at a lower level (37 – 40%) than their 
non-multiplexed counterparts (Figure 2C). This issue 
could be resolved by increasing plasmid DNA 
concentration before printing or reducing multiplicity 
per spot. Alternatively, since large proteins represent 
a small fraction of the proteome, a hybrid array 
containing multiplexed spots with plasmids encoding 
for proteins with low to moderate MWs and 
non-multiplexed spots for large proteins (> 65 kDa) 
could be employed. In addition, PTMs that occur 
during cell-free protein expression may affect the 
protein display or activity on M-NAPPA arrays [42]. 
We have observed that the human expression system 
contains the ability to phosphorylate some proteins 
(data not shown); other types of PTMs (e.g., 
glycosylation, acetylation) by the expression system 
are not well known or reported. In our studies, PTMs 
did not appear to affect protein expression, 
protein-protein interactions, or the identification of 
serological antigens on M-NAPPA when compared to 
NAPPA (Figure 2, Figures 4-7 and Figure S7).  
Conclusion  
We developed a method that multiplexes five 
different proteins within the same feature, called 
M-NAPPA, which significantly increases array 
density while decreasing experimental time and cost. 
Although we used this approach with NAPPA and 
HD-NAPPA, the same concept could be applied 
toward other microarray technologies or platforms. 
Our results show that M-NAPPA identified hits in 
protein interaction and serum screening studies, thus 
highlighting its potential to be employed in high 
throughput proteomics studies. 
Supplementary Material  
Supplementary Table S1-S5 and Supplementary 
Figures S1-S12. 
http://www.thno.org/v07p4057s1.pdf  
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